PL1691824T3 - Białka należące do rodziny Bcl-2 i ich fragmenty oraz ich zastosowanie u pacjentów z rakami - Google Patents

Białka należące do rodziny Bcl-2 i ich fragmenty oraz ich zastosowanie u pacjentów z rakami

Info

Publication number
PL1691824T3
PL1691824T3 PL04797460T PL04797460T PL1691824T3 PL 1691824 T3 PL1691824 T3 PL 1691824T3 PL 04797460 T PL04797460 T PL 04797460T PL 04797460 T PL04797460 T PL 04797460T PL 1691824 T3 PL1691824 T3 PL 1691824T3
Authority
PL
Poland
Prior art keywords
fragments
bcl
family
cancer patients
proteins belonging
Prior art date
Application number
PL04797460T
Other languages
English (en)
Inventor
Eivind Per Thor Straten
Mads Hald Andersen
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL1691824T3 publication Critical patent/PL1691824T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL04797460T 2003-11-19 2004-11-18 Białka należące do rodziny Bcl-2 i ich fragmenty oraz ich zastosowanie u pacjentów z rakami PL1691824T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US52311903P 2003-11-19 2003-11-19
DKPA200301716 2003-11-19
PCT/DK2004/000799 WO2005049073A2 (en) 2003-11-19 2004-11-18 Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
EP04797460A EP1691824B1 (en) 2003-11-19 2004-11-18 Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients

Publications (1)

Publication Number Publication Date
PL1691824T3 true PL1691824T3 (pl) 2009-08-31

Family

ID=39149116

Family Applications (2)

Application Number Title Priority Date Filing Date
PL09154734T PL2087904T3 (pl) 2003-11-19 2004-11-18 Zastosowanie terapeutyczne peptydów pochodzących z białek BcL-XL u pacjentów z rakiem
PL04797460T PL1691824T3 (pl) 2003-11-19 2004-11-18 Białka należące do rodziny Bcl-2 i ich fragmenty oraz ich zastosowanie u pacjentów z rakami

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL09154734T PL2087904T3 (pl) 2003-11-19 2004-11-18 Zastosowanie terapeutyczne peptydów pochodzących z białek BcL-XL u pacjentów z rakiem

Country Status (18)

Country Link
US (1) US7842294B2 (pl)
EP (2) EP2087904B1 (pl)
JP (2) JP4926714B2 (pl)
KR (2) KR101216655B1 (pl)
CN (1) CN1921878B (pl)
AT (1) ATE424842T1 (pl)
AU (1) AU2004290866B2 (pl)
CA (1) CA2546794C (pl)
DE (1) DE602004019965D1 (pl)
DK (2) DK2087904T3 (pl)
ES (2) ES2323588T3 (pl)
HK (1) HK1101131A1 (pl)
MX (1) MXPA06005738A (pl)
PL (2) PL2087904T3 (pl)
PT (1) PT1691824E (pl)
RU (1) RU2367468C2 (pl)
WO (1) WO2005049073A2 (pl)
ZA (1) ZA200604866B (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8283325B2 (en) * 2004-10-19 2012-10-09 Massachusetts Institute Of Technology Virus scaffold for self-assembled, flexible and light lithium battery
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
CN103288920B (zh) * 2003-01-30 2015-08-12 苏瓦克有限公司 存活蛋白衍生肽及其用途
US20130052215A9 (en) * 2003-09-26 2013-02-28 Eckhard Podack Tumor vaccine
WO2006034334A2 (en) 2004-09-21 2006-03-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
AU2011203535B2 (en) * 2005-02-04 2012-10-11 Survac Aps Survivin peptide vaccine
MX2007009219A (es) * 2005-02-04 2008-01-16 Survac Aps Vacuna de peptido de survivina.
CA2622504A1 (en) * 2005-09-09 2008-03-08 Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for inhibiting cell death or enhancing cel proliferation
WO2008116468A2 (en) * 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP3023436A1 (en) 2007-07-03 2016-05-25 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
EP2197908A2 (en) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
EP2254592B1 (en) * 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
KR20170078862A (ko) 2008-05-16 2017-07-07 타이가 바이오테크놀로지스, 인코포레이티드 항체 및 그 제조 방법
WO2010009350A2 (en) * 2008-07-16 2010-01-21 Burnham Institute For Medical Research Compositions and methods for modulating nod-like receptor activity and uses thereof
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
EP3916010A1 (en) 2008-08-28 2021-12-01 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same and methods of identifying agents that modulate myc
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
WO2010037397A1 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cmv immune monitoring
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
EP2491116A4 (en) * 2009-10-22 2013-12-11 Univ Jefferson CELL-BASED ANTI-RISK COMPOSITIONS AND METHOD FOR THEIR PREPARATION AND USE
CA2792910A1 (en) 2010-03-11 2011-09-15 Yusuke Nakamura Hjurp peptides and vaccines including the same
ES2930809T3 (es) 2010-08-24 2022-12-22 Univ Pittsburgh Commonwealth Sys Higher Education Vacunas contra el cáncer cerebral basadas en el péptido receptor de interleucina-13 alfa 2
LT3536334T (lt) 2012-05-16 2021-10-11 Stemline Therapeutics Inc. Vakcina nuo vėžio, nukreipta į vėžines kamienines ląsteles
EP3868387A1 (en) * 2012-07-20 2021-08-25 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
EP2961419A4 (en) * 2013-02-26 2016-12-21 Rongfu Wang PHF20 AND JMJD3 COMPOSITIONS AND METHOD FOR USE IN CANCER IMMUNOTHERAPY
EP3821898A1 (en) * 2013-03-01 2021-05-19 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of producing enriched populations of tumor-reactive t cells from tumor
US9704181B2 (en) * 2014-05-06 2017-07-11 International Business Machines Corporation Real-time social group based bidding system
CN113786476A (zh) 2016-12-02 2021-12-14 泰加生物工艺学公司 纳米颗粒调配物
SG11201906198PA (en) * 2017-01-27 2019-08-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
AR110857A1 (es) 2017-01-27 2019-05-08 Immatics Biotechnologies Gmbh Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer
MA47367B1 (fr) * 2017-01-27 2023-06-28 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
KR20210086612A (ko) 2018-09-04 2021-07-08 트레오스 바이오 리미티드 펩타이드 백신
CN113355432A (zh) * 2021-05-12 2021-09-07 甘肃农业大学 Bmf作为细胞凋亡标志物的应用
WO2022245249A1 (ru) * 2021-05-17 2022-11-24 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Пептидные соединения для индукции апоптоза в опухолевой клетке

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
WO1994005304A1 (en) 1992-08-31 1994-03-17 Ludwig Institute For Cancer Research Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof
US5470955A (en) * 1993-02-02 1995-11-28 Dartmouth College Antibodies which specifically bind mcl-1 polypeptide
US5646008A (en) * 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
US5700638A (en) * 1993-08-26 1997-12-23 Washington University Cell death regulator
GB9320597D0 (en) 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5789201A (en) * 1996-02-23 1998-08-04 Cocensys, Inc. Genes coding for bcl-y a bcl-2 homologue
ATE414149T1 (de) 1996-11-20 2008-11-15 Univ Yale Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation
WO1998058541A1 (en) * 1997-06-24 1998-12-30 Dana-Farber Cancer Institute, Inc. Modulation of apoptosis
WO2001036594A1 (en) * 1999-11-16 2001-05-25 Dartmouth College Mcl-1 GENE REGULATORY ELEMENTS AND A PRO-APOPTOTIC Mcl-1 VARIANT
AU2578401A (en) * 1999-12-14 2001-06-25 Burnham Institute, The Bcl-g polypeptides, encoding nucleic acids and methods of use
WO2002005835A2 (en) * 2000-07-17 2002-01-24 Washington University Modulation of apoptosis
AU2002257647A1 (en) 2001-03-09 2002-09-24 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
EP1618130B1 (en) 2003-04-11 2013-03-27 Survac ApS Therapeutic cancer vaccine

Also Published As

Publication number Publication date
ES2436429T3 (es) 2014-01-02
CA2546794A1 (en) 2005-06-02
PT1691824E (pt) 2009-05-28
JP2007511547A (ja) 2007-05-10
JP2011246496A (ja) 2011-12-08
EP1691824A2 (en) 2006-08-23
KR20130026527A (ko) 2013-03-13
ATE424842T1 (de) 2009-03-15
EP2087904B1 (en) 2013-08-28
EP1691824B1 (en) 2009-03-11
CN1921878A (zh) 2007-02-28
US7842294B2 (en) 2010-11-30
EP2087904A1 (en) 2009-08-12
ES2323588T3 (es) 2009-07-21
AU2004290866A1 (en) 2005-06-02
KR101216655B1 (ko) 2013-01-02
RU2367468C2 (ru) 2009-09-20
AU2004290866B2 (en) 2010-09-02
KR101284237B1 (ko) 2013-07-09
DK2087904T3 (da) 2013-12-02
JP4926714B2 (ja) 2012-05-09
CN1921878B (zh) 2012-04-25
WO2005049073A2 (en) 2005-06-02
PL2087904T3 (pl) 2014-01-31
WO2005049073A3 (en) 2006-01-05
KR20060132622A (ko) 2006-12-21
CA2546794C (en) 2013-09-17
JP5502823B2 (ja) 2014-05-28
MXPA06005738A (es) 2006-12-14
ZA200604866B (en) 2008-05-28
US20080050396A1 (en) 2008-02-28
DE602004019965D1 (de) 2009-04-23
DK1691824T3 (da) 2009-07-06
RU2006121466A (ru) 2007-12-27
HK1101131A1 (en) 2007-10-12

Similar Documents

Publication Publication Date Title
HK1101131A1 (en) Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
CA2523467C (en) Treatment of t-cell mediated diseases
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
WO2007034489A3 (en) Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
IL164643A (en) Peptides, immunogenic compositions containing them and use thereof for the preparation of medicaments for the treatment of alzheimer's disease
EP2182006A3 (en) Compositions and methods for the treatment of immune related diseases
AU2003270643A1 (en) Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
WO2001052791A3 (en) Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
HK1112367A1 (en) Survivin peptide vaccine
WO2006023598A3 (en) Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
WO2003016915A8 (en) Tumor specific oligosaccharide sequences and use thereof
PL371278A1 (pl) Zmodyfikowany czynnik VIII
ATE549353T1 (de) Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen
MX2007003624A (es) Peptidos y derivados tipo peptido ligando alterado de la hsp60 y composiciones farmaceuticas.
HUP0402071A2 (hu) Csökkentett immunogenitású, módosított leptin
DK1290160T3 (da) Humane Pellino-polypeptider
HUP0302566A2 (hu) Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására
EP1812035A4 (en) PEPTIDE ANTITUMOR AGENT
IL207012A (en) 28sgp medicinal product and 28sgp accent cancer treatment vaccine
EP2322209A3 (en) Tumor specific oligosaccharide epitopes and use thereof
GB0004576D0 (en) Proteins
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
EP1939217A3 (en) Plasmids coding for p185neu protein sequence variants and therapeutic uses thereof
WO2004031354A3 (en) Human sarcoma-associated antigens
HUP0303150A2 (hu) Csökkentett immunogenitású, módosított keratinocita növekedési faktor (KGF)